CNS Pharmaceuticals, Inc. (CNSP): Nasdaq/NYSE listing notice — CNS Pharma receives Nasdaq bid-price deficiency notice; board committee changes

CNS Pharmaceuticals, Inc.

On Feb 27, 2024, Nasdaq notified CNS Pharma common stock bid price closed below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
Company has 180 days until Aug 26, 2024 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.
This follows a prior delisting notice for failing to meet $2.5M stockholders' equity; hearing requested and stay granted.
Board appointed committee chairs: Audit (Keyes), Compensation (Gumulka), Nominating/Governance (Cockroft) effective Feb 21, 2024.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CNS Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 27, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq Listing Rule 58

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.